Geode Capital Management LLC Has $1.53 Million Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Geode Capital Management LLC raised its position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Free Report) by 259.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 238,737 shares of the company's stock after purchasing an additional 172,382 shares during the period. Geode Capital Management LLC owned 0.81% of Telomir Pharmaceuticals worth $1,533,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TELO. Barclays PLC raised its stake in Telomir Pharmaceuticals by 325.1% during the third quarter. Barclays PLC now owns 7,018 shares of the company's stock worth $45,000 after buying an additional 5,367 shares during the last quarter. Beaird Harris Wealth Management LLC raised its position in shares of Telomir Pharmaceuticals by 212.9% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company's stock worth $70,000 after acquiring an additional 9,950 shares in the last quarter. State Street Corp lifted its stake in shares of Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company's stock valued at $232,000 after purchasing an additional 17,967 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Telomir Pharmaceuticals in the 2nd quarter valued at about $241,000. Finally, Suncoast Equity Management boosted its position in shares of Telomir Pharmaceuticals by 109.9% during the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company's stock valued at $329,000 after purchasing an additional 26,803 shares in the last quarter.

Telomir Pharmaceuticals Trading Down 5.5 %

TELO stock traded down $0.25 during mid-day trading on Thursday, reaching $4.30. The company's stock had a trading volume of 91,320 shares, compared to its average volume of 118,844. Telomir Pharmaceuticals, Inc. has a 12 month low of $3.11 and a 12 month high of $20.72. The business's 50 day moving average price is $4.57 and its 200 day moving average price is $4.75.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.